Scleroderma Recruiting Phase 1 / 2 Trials for Brentuximab vedotin (DB08870)

Also known as: Dermatosclerosis

IndicationStatusPhase
DBCOND0013449 (Scleroderma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03222492Brentuximab Vedotin for Systemic SclerosisTreatment